Log In
Print this Print this

Zuplenz, ondansetron

  Manage Alerts
Collapse Summary General Information
Company MonoSol Rx LLC
DescriptionSelective serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent and treat nausea and vomiting; Prevent postoperative chemotherapy-induced and radiotherapy-induced nausea and vomiting
Regulatory Designation
PartnerMidatech Pharma plc;
R-Pharm CJSC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today